CSL112 vs Placebo: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0382 | 0.0344 | 0.0423 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.039 | 0.0352 | 0.0432 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.00079 | -0.0064 | 0.00482 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.98 | 0.848 | 1.13 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.979 | 0.842 | 1.14 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer death from any cause on CSL112 than on Placebo | 1,270 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | CSL112 | Participants received 6 grams of CSL112 (apoA-I purified from human plasma) once weekly via IV infusion for up to 4 weeks. | 348 | 9,112 | EG000 | ClinicalTrials.gov |
| Group 2 | Placebo | Participants received placebo (25% albumin solution diluted to 4.4%) once weekly via IV infusion for up to 4 weeks. | 355 | 9,107 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, all-cause mortality | ClinicalTrials.gov |
| Time frame | All AEs were collected through Day 90 and AEs related to study drug, those leading to its discontinuation, withdrawal of consent, all-cause mortality, Other AEs and all SAEs were collected up to Day 379 (Day 365+ 14 days of follow-up) | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome | ClinicalTrials.gov |
| NCT number | NCT03473223 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Acute Coronary Syndrome | ClinicalTrials.gov |
| Interventions | Apolipoprotein A-I [human] (apoA-I), Placebo | ClinicalTrials.gov |
| Lead sponsor | CSL Behring | ClinicalTrials.gov |
| Results first posted | 2025-01-14 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT03473223?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.